Delivery Order SPE2DB24D2011-SPE2DB25FBRMV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,991.73 to AmerisourceBergen Drug Corp for the supply of Vyvanse 50 mg capsules (100 count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. Vyvanse is a prescription stimulant medication commonly used to treat attention deficit...
- The Defense Logistics Agency awarded a delivery order valued at $6,321.44 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Vyvanse is a prescription medication used in the treatment of attention deficit hyperactivity...
- The Defense Logistics Agency awarded a delivery order valued at $2,189.62 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100 count). This non-set-aside, firm fixed price delivery order is scheduled for ultimate completion on August 6, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Vyvanse is a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder and binge eating disorder,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,337.70 on July 21, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This firm fixed-price delivery order, which is expected to be completed by July 22, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Vyvanse is a prescription medication commonly used in...
- The Defense Logistics Agency awarded a delivery order valued at $1,398.46 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder and binge eating disorder. The contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $3,007.07 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, under firm fixed pricing with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a $4.87K firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg, a prescription medication commonly used to treat attention deficit hyperactivity disorder and binge eating disorder. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $3,163.85 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, a prescription stimulant medication commonly used to treat attention-deficit/hyperactivity disorder. The contract, awarded on July 24, 2025, with completion targeted for July 25, 2025, carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be fulfilled from AmerisourceBergen's location in...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRMVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,775.04 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Vyvanse is a prescription medication commonly used to treat attention-deficit/hyperactivity disorder and binge eating disorder, representing part of the federal government's ongoing pharmaceutical procurement needs for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's status as a prime contractor demonstrates its capability to fulfill federal medical supply requirements through open competition, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/8/25 |